Drug ID:Drug172
Drug Name:BMS-986251
CID:132123624
DrugBank ID:DB19007
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT03329885
Molecular Formula:C30H29F8NO5S
Molecular Weight:667.6 g/mol
Isomeric SMILES:C[C@H]1C[C@@H](CC[C@H]1C(=O)N2CC[C@@]3([C@H]2CCC4=C3C=CC(=C4)C(C(F)(F)F)(C(F)(F)F)F)S(=O)(=O)C5=CC=C(C=C5)F)C(=O)O
Synonyms:BMS-986251; UNII-2WQX2MS3MQ; 2WQX2MS3MQ; (1R,3S,4R)-4-((3aR,9bR)-9b-((4-Fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-benzo(E)indole-3-carbonyl)-3-methylcyclohexane-1-carboxylic acid; 2041841-30-7; 2460133-35-9; (1R,3S,4R)-4-[(3aR,9bR)-9b-[(4-fluorophenyl)sulfonyl]-7-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-1,2,3a,4,5,9b-hexahydro-3H-benzo[e]indole-3-carbonyl]-3-methylcyclohexane-1-carboxylic acid; CHEMBL4634542; SCHEMBL19592747; JQORWGARJVSRBA-QOTTZFGFSA-N
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
No data available

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT04857112 Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Bausch Health Americas, Inc. Ulcerative Colitis DRUG: Low Dose MT-1303|DRUG: High Dose MT-1303|DR… Details
NCT02447302 Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis PHASE2 COMPLETED Arena Pharmaceuticals Ulcerative Colitis DRUG: Etrasimod|DRUG: Placebo Details
NCT02762500 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis PHASE2 COMPLETED Lycera Corp. Colitis, Ulcerative DRUG: LYC-30937-EC|DRUG: Placebo Details
NCT04677179 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) PHASE2 TERMINATED Nektar Therapeutics Colitis, Ulcerative DRUG: LY3471851|DRUG: Placebo Details
NCT03849599 A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis PHASE1 COMPLETED Provention Bio, Inc. Ulcerative Colitis BIOLOGICAL: PRV-300|BIOLOGICAL: Placebo Details
NCT02611830 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis PHASE3 COMPLETED Takeda Colitis, Ulcerative DRUG: Vedolizumab 300 mg IV|DRUG: Placebo IV|DRUG… Details
NCT05807971 Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects PHASE1 COMPLETED Athos Therapeutics Inc Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… DRUG: ATH-063|DRUG: Placebo Details
NCT02039505 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis PHASE3 COMPLETED Takeda Ulcerative Colitis DRUG: Vedolizumab|DRUG: Vedolizumab placebo Details
NCT05076175 A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis PHASE2|PHASE3 RECRUITING Bristol-Myers Squibb Colitis, Ulcerative DRUG: Ozanimod Details
NCT06636656 A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis PHASE2 RECRUITING Boehringer Ingelheim Ulcerative Colitis DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… Details
NCT04996797 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) PHASE2 ACTIVE_NOT_RECRUITING Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Ulcerative Colitis DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… Details
NCT01959282 A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis PHASE2 COMPLETED Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… Details
NCT06381518 Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease None ENROLLING_BY_INVITATION Zuyderland Medisch Centrum IBD|Infliximab|Crohn Disease|Ulcerative Colitis OTHER: Switch to SC CT-P13. Details
NCT00628433 Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis PHASE1|PHASE2 COMPLETED Harbor Therapeutics Ulcerative Colitis DRUG: Placebo|DRUG: HE3286 Details
NCT01877577 Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D None COMPLETED University of California, San Francisco Crohn's Disease (CD)|Ulcerative Colitis (UC) DIETARY_SUPPLEMENT: Vitamin D3 Details
NCT00317356 A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis PHASE2 TERMINATED Otsuka Pharmaceutical Co., Ltd. Colitis, Ulcerative DRUG: OPC-6535(Tetomilast) Details
NCT05019742 Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis PHASE2 RECRUITING Shanghai Pharma Biotherapeutics USA Inc. Ulcerative Colitis DRUG: SPH3127|DRUG: Placebo Details
NCT02601300 An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis PHASE2 COMPLETED Celgene Colitis, Ulcerative DRUG: GED-0301 Details
NCT06582264 A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis PHASE1 RECRUITING Microbiotica Ltd Ulcerative Colitis BIOLOGICAL: MB310|OTHER: Placebo|DRUG: Vancomycin Details
NCT03893565 Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis PHASE2 TERMINATED GlaxoSmithKline Colitis, Ulcerative DRUG: GSK2831781 - Double Blind Phase|DRUG: Place… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S01 Anti-inflammatory inflammatory 5-Aminosalicylates (5-ASAs); corticosteroids Crohn's disease and ulcerative colitis are the two main com… Details
S04 T-cell homing and retention T-cell trafficking vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab Inhibition of the interaction between α4β7 integrins on T c… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations